Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

ams.

-- In its alliance with GlaxoSmithKline (GSK), Pharmacopeia reported that

it received a $500 thousand milestone payment for identification of a

compound for advancement into lead optimization six months ahead of the

original schedule. The compound is being evaluated as a potential

treatment for inflammatory pain. Pharmacopeia has already received $10

million from GSK for completion of early discovery activities and is

entitled to receive an additional $5 million payment upon the

completion of additional early discovery activities. Pharmacopeia is

also entitled to success-based milestone payments totaling up to $83

million per program for any drug development program pursued through

the multi-program alliance and up to double-digit royalties on the

sales of any product commercialized by GSK from the alliance.

Subsequent to the end of the third quarter:

Pharmacopeia announced that it has licensed a Phase 1 selective androgen receptor modulator (SARM) program from BMS, including lead and back-up compounds. Pharmacopeia plans to develop the lead compound from this program, PS178990, as a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer- and AIDS-related cachexia. The SARM program has a broad portfolio of pending patent applications that, if granted, would provide intellectual property coverage to the SARM program through at least 2023. PS178990 has been well characterized by BMS both in pre-clinical studies and in a Phase 1 single ascending dose study. The company plans to conduct several Phase 1 studies in 2008, including a multiple ascending dose study of PS178990, to obtain additional safety and tolerability data before entering Phase 2.

In consideration for the SARM program license, Pharmacopei
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BRIC Gynecological Devices Market Outlook ... GlobalData,s new report, "BRIC Gynecological Devices Market Outlook ... BRIC Gynecological Devices market. The report provides value, ... and average prices (in US dollars) within market ... (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and ...
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... Pomerantz LLP is investigating claims on behalf ... the "Company") (NASDAQ: PDLI).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... and/or directors have violated Sections 10(b) and 20(a) of ... On September 17, 2014, the Company announced that On ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
... 2012 Synteract , Inc., a full-service contract ... developing new therapies to combat the growing issue of ... Great Strides fundraising walk to benefit the Cystic ... Rempex (on behalf of Aptalis Pharma) are also working ...
... Ind., May 2, 2012  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2012 third quarter dividend of $0.125 ... to shareholders of record as of the close of business ... HOLDINGS, INC. Hill-Rom is a leading worldwide manufacturer ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:9/17/2014)... 17, 2014 Final Cut Pro X plugin ... 5k from Pixel Film Studios. , “ProBlue 5k is a ... from good to epic,” said Christina Austin, CEO of Pixel ... 5k is a definite game changer.” , ProBlue 5k is ... any filmmaker ! This footage compilation of over 100 ...
(Date:9/17/2014)... September 17, 2014 People who struggle to ... head to http://www.perwickstrom.com and get the answer by ... to point out, is that a business plan and a ... work together, commented Per Wickstrom. “The way I view it ... a business strategy which is part two.” , According ...
(Date:9/17/2014)... Chicago IL (PRWEB) September 17, 2014 ... of Pseudomonas aeruginosa infections allegedly caused by Non-Sterile ... to learn more about their options for legal recourse. ... & Drug Administration (FDA) in March 2012, after the ... Pseudomonas aeruginosa at William Beaumont Hospital in Royal Oak, ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. ... to household chemicals known as phthalates might increase a ... reported in a new study. Children had nearly ... age 5 and 11 if their mothers were exposed ... thal-ates), the researchers found. The two phthalates were butylbenzyl ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 Prevention ... outbreak that is hospitalizing scores of infants, children and ... says Dr. Kirk Mahon, medical director of Legacy ER ... “There have been no reported cases of EV-D68 so ... and Louisiana, that could change,” he said. “Implementing prevention ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... ... ... , , ... ...
... , ... plans to address neighborhood concerns. , ... South Boston, MA (PRWEB) March 1, 2010 -- Fenway Bark today announced operational changes ... before the City of Boston Zoning Board of Appeal, to request an Interim Planning Overlay ...
... ... ... ... ...
... , ... ... ... ...
... ... , ... , , , ... MCKINNEY, ...
... ... , ... , , , , ... ...
Cached Medicine News:Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 2Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 4Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 5Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7Health News:Torchmark Corporation Declares Dividend and Resumes Stock Repurchases 2Health News:MedCath Corporation Announces Decision to Consider Strategic Options 2
... line of Surgical Microscope Accessories includes ... lenses, fiber optic cables, and fiberoptic ... Adaptor attaches directly to a Zeiss® ... used to mount the Photo Adaptor ...
Inquire...
... Femoral Compression System consists of a ... FemoStop Femoral Compression System.,Both devices work ... Hemostatic Dressing achieves topical hemostasis by ... while FemoStop Femoral Compression System provides ...
... system. It stores patient chart notes, x-rays, laboratory ... would normally put in a file folder. Your ... write them, file them, find them, determine billing ... lost. They find their way to your house ...
Medicine Products: